Administration of GRP77 neutralizing antibody-targeting CAF depletes CAF-secreted IL6 and IL8, thereby abolishing a stem cell-supporting niche and sensitizing breast cancer cells to doxycycline, leading to significant shrinkage of the tumor volume (Su et al., 2018), highlighting the therapeutic potential of targeting precise tumor-promoting CAF. Here, IL6 is linked to neoplasm.